BioSpace - Earlier Onset of d-Retrovirus-Induced Leukemia after ...
14 Sep 2009 ... Labor Market Reports · Education & Training ... observations enlighten a potential threat in splenectomized HTLV-1 carriers and justify a ...
http://www.biospace.com/PLos_Article.aspx?TheTitle=Earlier%2...
|
GSK reports Promacta®/Revolade® (eltrombopag) significantly ...
6 Dec 2008 ... GSK submitted a Marketing Authorisation Application (MAA) for eltrombopag in Europe ... Eltrombopag was discovered as a result of a research ...
http://www.gsk.com/media/pressreleases/2008/2008_pressreleas...
|
Protein A Columns for Immune Thrombocytopenia: Health Technology ...
OHTA is one component of the Agency for Health Care Policy and Research (AHCPR), ... However, no such system is currently approved for marketing by the Food and
Drug .... Splenectomy, which removes the principle site of platelet destruction
and ... A recent report by Muroi et al, (47). involved the use of protein A ...
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsarchive...
|
Annual Report on the Rare Diseases and Conditions Research ...
NHLBI activities related to rare disease research in FY 2000 are described ..... from the U.S. drug market a number of prescription and over-the-counter drugs
...... including steroids and splenectomy, but a majority eventually relapse,
...
http://rarediseases.info.nih.gov/ASP/html/reports/fy2000/nhl...
|
Study analysis shows that eltrombopag significantly improves ...
19 Jun 2006 ... Eltrombopag was discovered as a result of a research collaboration ... Financial Review and Prospects' in the company's Annual Report 2005. ...
http://www.gsk.com/media/pressreleases/2006/2006_06_19_GSK85...
|
Amgen's Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized ...
11 Dec 2007 ... Randomized Phase 3 Study of Nplate in Non-Splenectomized Patients (Abstract #565 ) ... M.D., director of Platelet Research, Weill Medical College, ... including
Amgen's most recent annual report on Form 10-K and most recent periodic ... Our
stock price may be affected by actual or perceived market ...
http://www.biospace.com/news_story.aspx?NewsEntityId=80112...
|
GlaxoSmithKline files for FDA approval of Promacta/Revolade ...
20 Dec 2007 ... GSK also plans to submit a Marketing Authorisation Application (MAA) for eltrombopag in Europe in 2008. ... such as corticosteroids, immunoglobulins and/
or splenectomy. ... GlaxoSmithKline — one of the world's leading research-based
... Review' in the company's Annual Report on Form 20-F for 2006. ...
http://www.gsk.com/media/pressreleases/2007/2007_12_20_GSK11...
|
PNEUMOVAX® 23
splenectomy are at increased risk for fulminant pneumococcal sepsis associated .... reports, pneumococcal vaccine may be given as early as several months ....
Other adverse experiences reported in clinical trials and/or in post-marketing
experience with .... Unpublished data; files of Merck Research Laboratories. ...
http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23...
|
GSK initiates repeat dosing study of its novel oral platelet ...
12 Apr 2007 ... examples of which include splenectomy, corticosteroids, immunoglobulins, cyclophosphamide and rituximab. ... Eltrombopag was discovered as a result of a
research collaboration ... approval in any market for any indication at this
time. ... in the company's Annual Report on Form 20-F for 2006. ...
http://www.gsk.com/media/pressreleases/2007/2007_04_12_GSK10...
|
Genentech: Newsroom: Press Releases: News Release December 10, 2001
Skip to Content for (none) Menu for (none) About Us Menu Research Menu Development .... Of the 12 patients who had undergone a splenectomy, three
patients (25 ... Genentech and IDEC co-market Rituxan in the United States,
Roche markets ...
http://www.gene.com/gene/news/press-releases/display.do?meth...
|
